Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival by Kim, Sung-Hwan et al.
Clinical Characteristics of Malignant Pericardial Effusion
Associated with Recurrence and Survival
Introduction
Malignant pericardial effusion is a serious manifestation of
advanced malignancies. A large autopsy series has reported that
8.1% of patients with malignancy had pericardial involvement and
2.7% experienced pericardial effusion (1). Malignant pericardial
effusion can lead to various adverse events including, chest discom-
fort, dyspnea, tachycardia, hypotension and cardiogenic shock,
although some patients remain undiagnosed until death. Because the
amount of pericardial fluid can only be semi-quantitatively estimated
through imaging modalities, it is difficult to evaluate the relationship
between pericardial fluid volume and its affect on the heart. 
The most effective method of managing malignant pericardial
effusion with imminent or recurrent tamponade has not been deter-
mined, although repeated pericardiocentesis (PCC) and surgical
drainage (pericardiostomy or pericardial window operation) have
been widely used. Pericardial instillation of anti-cancer drugs has
also been recommended (2-6). The selection of a management plan
for these patients depends on the patient’s expected survival time
and the probability of recurrence. Patients with pericardial effusion
with imminent or recurrent tamponade have shown poor survival
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Purpose
We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent
or overt tamponade.
Materials and Methods
Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant
pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion
and survival status was available for 98 patients. 
Results
Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with ad-
enocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio
[HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite
chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of re-
currence. Survival rates three months after pericardiocentesis differed significantly with the
type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocar-
cinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers,
respectively.
Conclusion
Recurrence and survival of patients with malignant pericardial effusion are dependent on the
type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the
lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but
pericardiocentesis is considered effective as palliative management in patients with other
cancers. 
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outcomes (7-9). Therefore, pericardial effusion in cancer patients
has been considered a very grave sign. However, recent improvement
in systemic treatment, including chemotherapy and molecular-targeted
therapy, has enabled us to re-evaluate clinical outcomes for patients
with malignant pericardial effusion. In addition, little is known about
recurrence and survival after drainage, although a report has described
practice patterns and outcomes for all types of pericardial effusion
(10). In contrast to malignant pericardial effusion, other kinds of
effusion, including those caused by surgery, infection and connective
tissue disease are relatively uncommon, rarely recur, and can be
relatively easily treated. Recent improvements in systemic treatment,
including chemotherapy and molecular-targeted therapy, have
allowed a re-evaluation of clinical outcomes for patients with malignant
pericardial effusion. We have therefore investigated clinical outcomes
after drainage for malignant pericardial effusion with imminent or
overt tamponade.
Materials and Methods
1 Patient population
We retrospectively identified 100 consecutive patients who un-
derwent successful PCC between August 2001 and June 2007 as
initial treatment for hemodynamically significant or symptomatic
malignant pericardial effusion. Hemodynamic significance was
defined as diastolic right ventricular outflow collapse and exaggerated
right atrial collapse during atrial systole (11). Of the 100 patients,
two were lost to follow up after PCC; thus, 98 were included in this
analysis. Malignant pericardial effusion was defined as the presence
of malignant cells in pericardial effusion or the drainage of exudate
effusion in patients with malignancy, in the absence of other causes,
such as post-operative effusion or tuberculosis. Patients were classified
by primary cancer type into four categories: adenocarcinoma of the
lung (ADL-L), squamous cell carcinoma of the lung (SQ-L), breast
cancer, and other cancers. 
Clinical characteristics and the cytology and biochemistry of
effusion fluid were evaluated. The study end points were recurrence
of pericardial effusion after PCC and death from any cause. Recurrence
was defined as a reaccumulation of pericardial effusion requiring
another pericardial procedure, either PCC, pericardial window
operation or surgical pericardiostomy. Information on patient vital
status and survival was collected from medical records and death
certificate data from the Korea National Statistical Office. We calcu-
lated the interval between the first PCC and the next drainage of
pericardial effusion. Except for one patient who had adenocarcinoma
of lung (ADC-L) and poor performance status, all patients received
chemotherapy after PCC. Chemotherapy responses were assessed
after two or three treatment cycles using Response Evaluation
Criteria in Solid Tumors (RECIST) criteria (12).  
2 PCC procedures
All PCCs were performed in the medical intensive care unit under
the guidance of two-dimensional echocardiography. The point of
minimal distance between the skin and maximal fluid accumulation
was chosen as an entry site. After insertion of a catheter (18F), using
the standard Seldinger technique, pericardial effusion was aspirated
as much as possible on site and the drainage catheter was allowed to
remain in place. Successful PCC, defined as adequate catheter
positioning and effective drainage, was verified by echocardiography
and chest radiography. The catheter position was confirmed by injection
of agitated saline contrast, if necessary. Subsequently, the effusion
was drained naturally (without negative pressure) for two days, and
the catheter was removed when there was no significant pericardial
effusion by echocardiography. No chemical agent was instilled.
3 Statistical analysis
Categorical variables, presented as counts and percentages, were
compared using the chi-square test for equality of proportions.
Continuous variables were presented as mean±standard deviation
and range. Recurrence-free survival and overall survival rates were
assessed using the Kaplan-Meier method and between group di-
fferences in survival curves were assessed using the log-rank test.
Mean follow-up time was calculated among censored observations
only. Predictors of recurrence-free survival and overall survival were
investigated by fitting univariate and multivariable Cox regression
models. Variables, including age, sex, primary cancer type, response
to subsequent chemotherapy, history of radiotherapy (before and
after PCC), signs of tamponade, drained effusion volume and results
of effusion analysis, were entered into a backward and forward
stepwise Cox proportional-hazards model to identify predictors of
recurrence. Variables with a probability value ＜0.2 were retained.
All p-values were two sided and p＜0.05 was considered statistically
significant. Stata/SE 10.0 for Windows (Stata Corp LP, College
Station, TX) was used for all statistical analyses.
Results
1 Patient characteristics
Patient baseline demographic and clinical characteristics are listed
in Table 1. Fifty seven patients had ADC-L, 11 had SQ-L, 10 had
breast cancer, and 20 had other kinds of cancer; including 3 with
small cell carcinoma of the lung, 2 each with unspecified non-small
cell lung cancer, uterine cancer, stomach cancer, and colon cancer,
and 1 each with lymphoma, large cell carcinoma of the lung,
mesothelioma, osteosarcoma, bladder cancer, prostate cancer, bileCancer Res Treat. 2010;42(4):210-216
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tract cancer, esophageal cancer and thymic cancer. Therefore, the
predominant tumor type was lung cancer, present in 74 of 98 (76%)
patients, including 57 with ADC-L, 11 with SQ-L, 3 with small cell
lung cancer, 1 with large cell lung cancer and 2 with non-specified
lung cancer. Malignant cells were observed in the pericardial
effusion of 75 patients (77%). Although 23 patients (23%) were
negative for malignant cells, exudate effusion was drained from the
patients with malignancy and without other causes, such as post-
operative effusion or tuberculosis. Therefore, these patients were
regarded as having malignant pericardial effusion. According to
RECIST criteria, 74 patients had progressive disease after first
chemotherapy, 2 had complete response, 10 had partial response and
12 had stable disease. Of the 75 patients with lung cancer, 13 (17%)
received targeted therapy. The time from diagnosis to first PCC also
varied. Including the 15 patients (15%) who underwent PCC as the
initial manifestation of cancer, the median time between cancer
diagnosis and drainage of pericardial effusion was 10.2 months, and the
mean volume of drained pericardial effusion was 1,148±494 mL
(range, 370 to 2,300 mL). Most pericardial fluid samples (69/98,
70%) were grossly bloody. The mean effusion to serum ratio of red
blood cell (RBC) concentration was 0.3±0.3 (range, 0 to 1.4) and
was＞0.5 in 17% (14/84) of patients. In 3/84 patients (3.6%), RBCs
were more concentrated in the pericardial fluid than in the serum,
but there was no evidence of PCC-related hemorrhage. Interestingly,
effusion recurred only in patients with ADC-L or adenocarcinoma of
other organs (prostate, stomach, and colon). 
2 Predictors of recurrence of pericardial effusion
Pericardial effusions recurred in 30 patients (31%); of these, 12
underwent urgent surgical drainage, 11 underwent repeated PCC
with subsequent pericardial window operations, and 7 underwent
repeated PCC without subsequent pericardial window operations.
The mean follow-up time in these 30 patients was 9.7 months. The
cumulative probabilities of recurrence were 30% at 6 months and
52% at 12 months (Fig. 1A). Recurrence was dependent on the type
of primary cancer (Fig. 1B) and response to chemotherapy (Fig.
1C). Univariate analysis showed that ADC-L, progressive disease
after chemotherapy, and a lower proportion of polynuclear cells in
the effusion fluid were significantly associated with time to recurrence.
Positive cytology and the effusion to serum ratio of RBC tended to
show associations with recurrence, but these associations did not
reach statistical significance (Table 2). Although, some patients
received radiotherapy before (19%) and/or after (8%) PCC, radio-
therapy did not affect recurrence of pericardial effusion (Table 2). In
multivariable analysis, ADC-L (hazard ratio [HR], 6.6; 95% confi-
dence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease
(HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) remained significant
predictors for the recurrence of pericardial effusion. Among lung
cancer patients, those with adenocarcinomas were vulnerable to
recurrence of effusion, whereas those with squamous cell carcinoma
were not.
Total ADC-L* SQ-L
� Breast cancer Other cancer
(n=98) (n=57) (n=11) (n=10) (n=20) p-value
Clinical characteristics
Effusion recurrence 30 (31%) 27 (47%) 0 (0%) 0 (0%) 3 (15%) ＜0.001
Men 49 (50%) 29 (51%) 9 (82%) 0 (0%) 11 (55%) 0.002
Age (yr) 52±12 53±10 60±6 45±11 49±18 0.02
From diagnosis to PCC
�(mo) 18±22 12±16 14±8 57±34 20±16 ＜0.001
Positivity of cytology 75 (77%) 50 (88%) 4 (36%) 9 (90%) 12 (63%) 0.001
Drained volume (mL) 1,148±494 1,068±489 1,177±616 1,373±654 993±350 0.35
Progressive disease 73 (76%) 42 (75%) 9 (82%) 4 (40%) 18 (90%) 0.03
Fluid analysis 
RBC
§(/mm
3)1 0 ×10
5±10×10
5 9×10
5±11×10
5 7×10
5±9×10
5 16×10
5±10×10
5 10×10
5±11×10
5 0.26
Effusion/serum for RBC 0.3±0.3 0.3±0.3 0.2±0.3 0.5±0.3 0.3±0.3 0.26
WBC
‖(/mm
3) 3,304±3,527 3,229±3,410 2,923±4,431 4,599±3,782 3,186±3,348 0.75
Polynuclear (%) 24±21 16±13 46±27 16±14 35±24 ＜0.001
Mononuclear (%) 33±36 30±19 27±20 26±19 47±67 0.30
Other (%) 46±24 54±21 27±22 57±19 33±23 ＜0.001
Protein (mg/dL) 4,414±1,277 4,359±1,252 3,856±1,042 4,781±1,265 4,682±1,422 0.27
Glucose (mg/dL) 89±53 82±50 110±55 79±25 98±68 0.33
LDH
¶(mg/dL) 1,799±7,565 1,110±940 7,392±21,946 1,058±757 884±642 0.08
Chloride (mg/dL) 104±13 102±16 103±6 105±7 107±7 0.62
Amylase (mg/dl) 182±488 299±621 36±57 27±31 19±12 0.07
Table 1. Baseline characteristics according to the type of primary cancer
*adenocarcinoma of lung, 
�squamous cell carcinoma of lung, 
�pericardiocentesis, 
§ red blood cell, 
‖white blood cell, 
¶lactate dehydrogenase.Sung-Hwan Kim, et al_Treatment of Malignant Pericardial Effusion
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Fig. 1. Recurrences of malignant pericardial effusion. (A) Overall
recurrence rates after first pericardiocentesis. (B) Recurrence rates in
patients with different types of primary cancer. (C) Association
between recurrence rate and response to chemotherapy. No recurrence
of pericardial effusion was observed in patients with breast cancer
and squamous cell carcinoma of the lung. Therefore, two lines were
overlaid in (B).
Variable
Univariate analysis Multivariable analysis*
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age 1.0 (1.0-1.0) 0.86 - -
Gender (male) 0.9 (0.4-2.0) 0.79 - -
ADC-L*
,� 7.2 (2.1-24.3) ＜0.01 6.6 (1.9-22.3) 0.003
Progressive disease*(after chemotherapy) 4.6 (1.6-13.0) ＜0.01 4.3 (1.6-12.0) 0.005
Positive cytology 3.7 (0.9-15.4) 0.08 - -
PCC�within 6 mo of diagnosis 0.7 (0.3-1.4) 0.28 - -
Radiotherapy before PCC 2.2 (0.6-7.2) 0.21 - -
Radiotherapy after PCC 0.9 (0.2-3.7) 0.83 - -
Effusion/serum for RBC§ 0.2 (0.1-1.0)  0.05 - -
WBC‖ 1.0 (1.0-1.0) 0.07 - -
Polynuclear* 1.0 (0.9-1.0) 0.02 - -
Mononuclear 1.0 (1.0-1.0) 0.57 - -
Other cell 1.0 (1.0-1.0) 0.29 - -
Table 2. Univariate and multivariable cox regression analyses of time to effusion recurrence
*from one multivariable Cox regression model (variables were adjusted simultaneously in the same model), 
�adenocarcinoma of lung, 
�pericardiocentesis, 
§ red blood cell, 
‖white
blood cell.Cancer Res Treat. 2010;42(4):210-216
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3 Survival after PCC
Median overall survival after PCC was 5.0 months. Deaths were
observed in 89 patients (91%). The probability of overall survival
was 45%at 6 months and 26%at 12 months (Fig. 2A). The probability
of overall survival differed significantly by the type of primary
cancer and response to chemotherapy. Breast cancer patients showed
significantly better overall survival than did other groups (vs. ADL-
L, p=0.02; vs. SQ-L, p=0.002; vs. other cancers, p=0.02) (Fig. 2B),
which may have been due to the lower rate of progressive disease in
breast cancer patients (4/10, 40%). Overall survival was better in
patients with ADC-L than those with SQ-L or other cancers. Median
survival after PCC was 6.8 months in patients with ADC-L, 1.9
months in patients with SQ-L, 16.5 months in patients with breast
cancer, and 1.7 months in patients with other cancers. The probabilities
of survival 3 months after PCC in these 4 groups were 73%, 18%,
80% and 30%, respectively. In addition, the survival rates 1 year
after PCC were not so discouraging in patients with ADC-L (26%)
and breast cancer (47%). Progressive disease after PCC was also
significantly associated with overall survival time (Fig. 2C). 
Discussion
PCC-related major complications, including chamber laceration,
injury to intercostal vessels, pneumothorax, ventricular tachycardia
and bacteremia have been reported to be rare (14/1,127, 1.2%), as has
PCC-related mortality (1/1,127, 0.09%) (10). PCC is considered safe
for patients with significant pericardial effusion, although it requires
experience and skill and is only a temporary resolution. Therefore,
PCC is quite effective for patients with rarely recurrent pericardial
effusion, including those with idiopathic effusion, heart failure, uremia,
tuberculosis, myocardial infarction, connective tissue disease, or
with pericardial effusion due to well controlled diseases such as
hypothyroidism (13). In contrast, recurrent malignant pericardial
effusion is common, and the life expectancy of these patients is
limited due to advanced cancer (Table 3). 
We found that the recurrence rate after PCC differed according to
the type of primary cancer and response to chemotherapy. To our
knowledge, the present study is the largest to date to assess long-
term outcomes in patients with malignant pericardial effusion, and
to show that long-term outcome depends on the type of primary
cancer. Patients with malignant pericardial effusion from breast
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Fig. 2. Survival outcomes. (A) Overall survival rate after first peri-
cardiocentesis. (B, C) Survival rates according to the type of primary
cancer (B) and response to chemotherapy (C).Sung-Hwan Kim, et al_Treatment of Malignant Pericardial Effusion
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cancer showed longer survival times and lower recurrence rates than
did other patients, suggesting that PCC may be an effective solution
for patients with malignant pericardial effusion from breast cancer.
Patients with malignant pericardial effusion from SQ-L had a poor
survival rate (18% at 3 months) and there may be little chance of
recurrence. PCC is also effective as palliative management in patients
with such poor survival. However, patients with ADC-L had better
survival rates than those with SQ-L or other cancers, and pericardial
effusion recurred in many patients with ADC-L. ADC-L was signi-
ficantly associated with both recurrence and higher survival rate,
probably due to a better response to chemotherapy. Thus, patients
with ADC-L may be good candidates for surgical drainage to avoid
repeated PCC. 
Although most surgical drainages are performed under general
anesthesia, they are quite effective in avoiding the recurrence of
pericardial effusion (14). Another independent predictor of recurrence
was progressive disease. Therefore, response to chemotherapy should
be considered when selecting a therapeutic option for pericardial
effusion. Malignant cells were more frequently observed in patient
with recurrent effusions than those with non-recurrent effusion, but
the difference was not statistically significant. 
Abnormal cytology has been reported to predict poor prognosis
(8). In that study, however, cytology analyses were not performed
for all patients, and the proportion of patients with lung cancer,
which had the highest positive cytology rate, was lower than in our
study. A lower proportion of polynuclear cells is indicative of higher
proportions of other cells, including malignant cells, but these findings
also did not correlate with recurrence. Thus, the correlation between
recurrence and cytology requires further investigation. 
The effusion to serum ratio of RBC concentration varied consi-
derably and was even greater than in some patients without evidence
of hemorrhage. Therefore, unlike patients with hemothorax, it may
not be appropriate to differentiate among patients with pericardial
fluid by their effusion to serum RBC ratio. 
Conclusion
The overall recurrence rate of malignant pericardial effusion was
31% and the median survival after first PCC was 5.0 months, although
survival times varied considerably, from 0 to more than 10 years.
Recurrences of pericardial effusion occurred exclusively in patients
with adenocarcinoma (lung, prostate, stomach and colon), with ADC-L
and progressive disease being significant predictors of recurrence.
Median survival after first PCC in patients with ADC-L was -6.8
months, and this may be increased due to recent advances in chemo-
therapy. These findings highlight the importance of appropriate
management of malignant pericardial effusion, along with active
treatment of the primary cancer. Surgical interventions, such as
pericardial window operation, may be warranted in selected patients,
especially those with ADC-L, to prevent recurrent pericardial tam-
ponade. Although this study is retrospective in design and involves
patients from a single center, our findings suggest that the approach
to malignant pericardial effusion should be individualized based on
the type of primary cancer and patient response to chemotherapy.
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